Related Experiment Video
Updated: Jun 7, 2025

08:51
Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing
Published on: March 15, 2019
12.3K
p-IgGen: a paired antibody generative language model.
Oliver M Turnbull1, Dino Oglic2, Rebecca Croasdale-Wood3
1Department of Statistics, University of Oxford, Oxford, OX1 3LB, United Kingdom.
Bioinformatics (Oxford, England)
|November 9, 2024
Summary
We developed p-IgGen, a protein language model to generate novel antibody sequences. This tool helps overcome challenges in antibody drug discovery by designing sequences with improved developability and biophysical properties.
Area of Science:
- Biochemistry
- Computational Biology
- Drug Discovery
Background:
- Antibody drug discovery faces challenges in designing sequences with optimal developability.
- Issues such as aggregation, polyspecificity, poor expression, and low solubility hinder therapeutic antibody development.
Purpose of the Study:
- To present p-IgGen, a novel protein language model for paired heavy-light chain antibody generation.
- To develop a fine-tuned version of p-IgGen for generating antibodies with desirable 3D biophysical properties.
Main Methods:
- Utilized a protein language model for antibody sequence generation.
- Trained and fine-tuned the p-IgGen model on antibody sequence data.
- Evaluated generated sequences for antibody-like properties and biophysical characteristics.
Main Results:
- p-IgGen generates diverse, antibody-like sequences with natural pairing properties.
- The fine-tuned model biases generation towards antibodies with clinical-stage biophysical distributions.
- The model addresses key developability challenges in antibody design.
Conclusions:
- p-IgGen offers a powerful tool for designing novel antibody sequences with enhanced developability.
- The model facilitates the generation of therapeutic antibodies with improved biophysical properties.
- This approach aids in overcoming critical hurdles in antibody drug discovery.
Related Concept Videos
Antibody Structure
59.1K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
59.1K
Antibody Structure and Classes
831
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
831
Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K

